Genmab states that Darzalex/Faspro royalties are reduced in territories without patent coverage and that the U.S. patent expiry causes a material decline, not necessarily an immediate 100% loss of U.S.-related royalties. The patent dates disclosed by Genmab are years, not exact calendar dates. No specific patent-family expiry data; Continue reading Genmab Asymmetries →